✦ LIBER ✦

Cause of death in patients with lower-risk myelodysplastic syndrome

✍ Scribed by Farshid Dayyani; Anthony P. Conley; Sara S. Strom; William Stevenson; Jorge E. Cortes; Gautam Borthakur; Stefan Faderl; Susan O'Brien; Sherry Pierce; Hagop Kantarjian; Guillermo Garcia-Manero

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 212 KB
Volume: 116
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.24984

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Subcutaneous or intravenous administrati

Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes

✍ Mikkael A. Sekeres; Hagop Kantarjian; Pierre Fenaux; Pamela Becker; Adam Borucho 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 355 KB

Amifostine plus erythropoietin in a pati

Amifostine plus erythropoietin in a patient with low-risk myelodysplastic syndrome

✍ E. Musch; M. Malek; A. Chrissafidou 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 138 KB

Cigarette smoking shortens the survival

Cigarette smoking shortens the survival of patients with low-risk myelodysplastic syndromes

✍ Xiaomei Ma; Rong Wang; Naomi Galili; Susan T. Mayne; Sa A. Wang; Herbert Yu; Azr 📂 Article 📅 2011 🏛 Springer Netherlands 🌐 English ⚖ 197 KB

Oxidative DNA damage in bone marrow cell

Oxidative DNA damage in bone marrow cells of patients with low-risk myelodysplastic syndrome

✍ Bozena Novotna; Yana Bagryantseva; Magda Siskova; Radana Neuwirtova 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 301 KB

Iron overload and chelation therapy in p

Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements

✍ Angel F. Remacha; Beatriz Arrizabalaga; Consuelo Del Cañizo; Guillermo Sanz; Ana 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 147 KB

Azacitidine for the treatment of lower r

Azacitidine for the treatment of lower risk myelodysplastic syndromes : A retrospective study of 74 patients enrolled in an Italian named patient program

✍ Pellegrino Musto; Luca Maurillo; Alessandra Spagnoli; Antonella Gozzini; Flavia 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 203 KB 👁 2 views

## Abstract ## BACKGROUND: Azacitidine induces responses and prolongs overall survival compared with conventional care regimens in patients who have high‐risk myelodysplastic syndromes (MDS). However, limited data are available concerning the efficacy and safety of azacitidine in patients who have